WallStreetZenWallStreetZen

NASDAQ: PLRX
Pliant Therapeutics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for PLRX

Based on 1 analyst offering 12 month price targets for Pliant Therapeutics Inc

Min Forecast
$2.00+76.99%
Avg Forecast
$2.00+76.99%
Max Forecast
$2.00+76.99%

Should I buy or sell PLRX stock?

Based on 1 analyst offering ratings for Pliant Therapeutics Inc.

Hold
Strong Buy
0 analysts 0%
Buy
0 analysts 0%
Hold
1 analysts 100%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Our proven Zen Rating quant model agrees with analyst consensus with a "Hold" rating. Learn More

Be the first to know when Wall Street analysts revise their PLRX stock forecasts and price targets.

PLRX stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-11-07

1 of 1

Forecast return on equity

Is PLRX forecast to generate an efficient return?

Company
-71.14%
Industry
285.61%
Market
238.21%
PLRX's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is PLRX forecast to generate an efficient return on assets?

Company
-51.51%
Industry
114.65%
PLRX is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

PLRX earnings per share forecast

What is PLRX's earnings per share in the next 3 years based on estimates from 10 analysts?

Avg 1 year Forecast
-$2.54
Avg 2 year Forecast
-$1.12
Avg 3 year Forecast
-$3.59

PLRX revenue forecast

What is PLRX's revenue in the next 3 years based on estimates from 9 analysts?

Avg 1 year Forecast
$0.0
Avg 2 year Forecast
$3.8M
Avg 3 year Forecast
$18.7M

PLRX vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
PLRX$1.13$2.00+76.99%Hold
PYPD$4.41$11.00+149.43%Strong Buy
NBY$0.54N/AN/A
XBIT$2.34N/AN/A
ACET$7.04$89.00+1,164.20%Strong Buy
View Top Biotech Stocks

Pliant Therapeutics Stock Forecast FAQ

Is Pliant Therapeutics Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NASDAQ: PLRX) stock is to Hold PLRX stock.

Out of 1 analyst, 0 (0%) are recommending PLRX as a Strong Buy, 0 (0%) are recommending PLRX as a Buy, 1 (100%) are recommending PLRX as a Hold, 0 (0%) are recommending PLRX as a Sell, and 0 (0%) are recommending PLRX as a Strong Sell.

If you're new to stock investing, here's how to buy Pliant Therapeutics stock.

What is PLRX's earnings growth forecast for 2026-2028?

(NASDAQ: PLRX) Pliant Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 62.75%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 39.88%.

Pliant Therapeutics's earnings in 2026 is -$175,499,000.On average, 10 Wall Street analysts forecast PLRX's earnings for 2026 to be -$155,976,974, with the lowest PLRX earnings forecast at -$399,863,438, and the highest PLRX earnings forecast at -$89,040,159. On average, 8 Wall Street analysts forecast PLRX's earnings for 2027 to be -$68,823,311, with the lowest PLRX earnings forecast at -$108,998,919, and the highest PLRX earnings forecast at $18,711,338.

In 2028, PLRX is forecast to generate -$220,627,872 in earnings, with the lowest earnings forecast at -$401,670,050 and the highest earnings forecast at -$111,622,808.

What is PLRX's revenue growth forecast for 2026-2028?

(NASDAQ: PLRX) Pliant Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 116.48%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 24.03%.

Pliant Therapeutics's revenue in 2026 is $0.On average, 9 Wall Street analysts forecast PLRX's revenue for 2026 to be $0, with the lowest PLRX revenue forecast at $0, and the highest PLRX revenue forecast at $0. On average, 7 Wall Street analysts forecast PLRX's revenue for 2027 to be $235,043,898, with the lowest PLRX revenue forecast at $0, and the highest PLRX revenue forecast at $967,827,814.

In 2028, PLRX is forecast to generate $1,147,014,220 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $4,290,703,308.

What is PLRX's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: PLRX) forecast ROA is -51.51%, which is lower than the forecast US Biotechnology industry average of 114.65%.

What is PLRX's Price Target?

According to 1 Wall Street analyst that have issued a 1 year PLRX price target, the average PLRX price target is $2.00, with the highest PLRX stock price forecast at $2.00 and the lowest PLRX stock price forecast at $2.00.

The Wall Street analyst predicted that Pliant Therapeutics's share price could reach $2.00 by Nov 7, 2026. The average Pliant Therapeutics stock price prediction forecasts a potential upside of 76.99% from the current PLRX share price of $1.13.

What is PLRX's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: PLRX) Pliant Therapeutics's current Earnings Per Share (EPS) is -$2.87. On average, analysts forecast that PLRX's EPS will be -$2.54 for 2026, with the lowest EPS forecast at -$6.51, and the highest EPS forecast at -$1.45. On average, analysts forecast that PLRX's EPS will be -$1.12 for 2027, with the lowest EPS forecast at -$1.77, and the highest EPS forecast at $0.30. In 2028, PLRX's EPS is forecast to hit -$3.59 (min: -$6.54, max: -$1.82).

What is PLRX's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: PLRX) forecast ROE is -71.14%, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.